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Heparin cofactor I1 and antithrombin are plasma 
serine  proteinase  inhibitors whose ability  to  inhibit a- 
thrombin  is  accelerated by  glycosaminoglycans. Dys- 
functional  thrombin  mutants Quick I (Arg“ + Cys) 
and Quick I1 (GlyZz6 + Val) were used  to further com- 
pare heparin  cofactor I1 and  antithrombin  interactions. 
Quick I, Quick 11, and  a-thrombin  were  eluted  at  the 
same  salt  concentration  from  heparin-Sepharose sug- 
gesting that the putative heparin-binding site (also 
termed anion binding exosite-11) is functional. Anti- 
thrombin yielded similar  inhibition rates for Quick I 
and  a-thrombin  in  the  absence or presence of various 
amounts of heparin. Also, Quick I was  inhibited simi- 
larly to  a-thrombin by heparin  cofactor I1 in  the  ab- 
sence of glycosaminoglycan. In contrast, glycosami- 
noglycan-accelerated  Quick I inhibition  by  heparin CO- 
factor I1 was greatly reduced indicating that anion 
binding  exosite-I  (where  the  mutation  occurs  in Quick 
I) is critical  for  increased  inhibition by heparin cofac- 
tor 11. We also  found that  heparin  cofactor I1 formed a 
SDS-resistant bimolecular  complex with Quick I1 and 
a-thrombin  at  similar  rates  and  the  rate of complex 
formation  was  accelerated  in  the  presence of glycosa- 
minoglycans. A three-dimensional  molecular model of 
the Quick I1 active  site  compared  to  a-thrombin sug- 
gested  that  the  heparin  cofactor I1 Leu-Ser-reactive 
site sequence (Pl-Pl’) is a compatible “pseudosub- 
strate”  in  contrast  to  the  Arg-Ser  sequence  found  in 
antithrombin.  The  importance of heparin  cofactor I1 
as a thrombin  regulator  will  depend upon its  ability  to 
interact  with glycosaminoglycans and  the  functional 
availability of thrombin exosites. 
a-Thrombin is an  important enzyme in  both  the  activation 
and  attenuation of hemostasis (Refs. 1-3, and references cited 
therein).  Its reactivity is regulated by a number of proteins, 
including antithrombin, heparin cofactor 11, and thrombo- 
modulin (4-6). Thrombin  interacts  with  many  substrates  and 
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regulatory proteins  both  through  the active site  and  through 
secondary binding  domains, called  “exosites” (2, 3, 7-9). An- 
ion binding exosite-I (comprised of residues Arg67 to Glum, 
Arg35, L Y S ~ ~ ,  Lys’’,  Lys1Og,  Lys”’, and  L~s’~’~)’   has  been shown 
to  bind fibrinogen, hirudin,  and  thrombomodulin (2, 3, 7-15). 
Anion binding exosite-I1 (comprised of arginyl residues 93, 
97, 101, 126, 165, 173, 175, and 263 and lysyl residues 169, 
235,  236, and 240) is  the  putative  heparin-binding region and 
is located on  the surface of a-thrombin opposite anion  binding 
exosite-I (Refs. 3 and 16, and references cited  therein).  Char- 
acterization of thrombin  mutants  and derivatives of a-throm- 
bin  generated by limited proteolysis and chemical modifica- 
tion has been instrumental in defining the structural and 
functional requirements of protein and glycosaminoglycan 
interactions. 
Heparin cofactor I1 and antithrombin (historically called 
antithrombin 111) are  members of the  serine  proteinase  inhib- 
itor  (serpin)’ superfamily of proteins  (for a review, see Refs. 
4, 5 ,  and 17-19). Inhibition of thrombin by both serpins is 
greatly  accelerated in  the presence of the glycosaminoglycan 
heparin, but several differences between antithrombin and 
heparin cofactor I1 are  apparent  (4, 5, 17-23). Antithrombin 
inhibits most of the coagulation pathway enzymes and its 
activity can be accelerated by heparin and heparan sulfate 
(4).  In  contrast,  heparin cofactor I1 inhibits only thrombin in 
coagulation and a variety of glycosaminoglycans and other 
polyanions  are capable of enhancing  this  inhibition  (5).  The 
reactive-site  P1-P1’ residues of heparin cofactor I1 are Leu- 
Ser,  distinct from the Arg-Ser in  antithrombin  and most other 
thrombin  substrates (4, 18). Additionally, heparin cofactor I1 
possesses a distinct acidic amino-terminal domain  (24). These 
unique  structural differences  suggest that  antithrombin  and 
heparin cofactor I1 utilize different mechanisms  for thrombin 
inhibition.  Examination of heparin cofactor I1 inhibition of 
human  a-, t- and  yT-thrombin  demonstrated a requirement 
of both  anion  binding exosite-I and -11 for efficient glycosa- 
minoglycan acceleration of proteinase inhibition (25). Fur- 
thermore,  studies with recombinant  heparin cofactor I1 indi- 
cate a role for the  unique acidic amino-terminal domain in 
the glycosaminoglycan-accelerated inhibition of thrombin 
(26-28). This is in contrast  to  antithrombin, which requires 
only anion  binding exosite-I1 for accelerated inhibition of a -  
thrombin or its proteolyzed t and YT derivatives (25). 
The numbering of thrombin residues is based on  chymotrypsin- 
ogen as described by Bode et al. (10). 
The abbreviations used are: serpin, serine proteinase inhibitor; 
Chromozym-TH, Ne-p-tosyl-Gly-Pro-Arg-p-nitroanilide; FPR, D- 
Phe-Pro-Arg chloromethyl  ketone; FPL,  D-Phe-Pro-Leu  chloro- 
methyl ketone; HEPES, 4-(2-hydroxylethyl)-l-piperazineethanesul- 
fonic  acid; PAGE, polyacrylamide gel electrophoresis. 
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The work described here used the  naturally occurring 
thrombin  mutants, Quick I and 11. Quick I has  an + 
CYS  substitution which is located in  the p-loop region of a -  
thrombin,  part of anion  binding  exosite-I (15). This  thrombin 
variant has greatly reduced fibrinogen hydrolysis, factor V 
activation,  and  platelet aggregation activity  (15,29, 30). How- 
ever, Quick I does form a bimolecular complex with anti- 
thrombin, and it interacts normally with the active site- 
directed  inhibitor diisopropyl fluorophosphate  (30).  In Quick 
11, a GlyLZ6 + Val substitution in the primary substrate 
binding pocket results  in a dramatic loss of catalytic  activity 
toward  normal  thrombin  substrates,  and i ability to hydrolyze 
fibrinogen (31). We report that for Quick I (Arg67 -+ Cys), 
inhibition by antithrombinlheparin is unaltered, whereas 
there  is a dramatic difference in glycosaminoglycan-acceler- 
ated  inhibition by heparin cofactor I1 when  compared to  the 
corresponding inhibition of @-thrombin. We further show that 
Quick I1 (G1yZz6 + Val) forms a bimolecular complex with 
heparin cofactor 11, but  not  antithrombin,  and  that  formation 
of the complex can be accelerated by glycosaminoglycans. 
Molecular modeling of Quick I1 and  a-thrombin suggests that 
differences in reactivity with heparin cofactor I1 and anti- 
thrombin are attributable to the difference in the serpin 
reactive-site residues. 
EXPERIMENTAL PROCEDURES 
Materials-Heparin cofactor 11, antithrombin, and prothrombin 
were  purified from outdated  human  plasma  as previously  described 
(32).  a-Thrombin was generated  from  prothrombin  and purified as 
detailed  (33). yT-Thrombin was prepared by  limited  proteolysis of a- 
thrombin  with  trypsin (11). Thrombin Quick I and I1 were prepared 
from  dysprothrombin Quick isolated  from plasma  as described pre- 
viously (34). Heparin, dermatan sulfate, Polybrene, and heparin- 
Sepharose were obtained from Diosynth BV (Oss, the  Netherlands), 
Calbiochem, Aldrich, and Pharmacia LKB Biotechnology, respec- 
tively. Dermatan  sulfate was nitrous  acid-treated to  remove contam- 
inating heparin and heparan sulfate (35). Chromozym-TH (Ne-p- 
tosyl-Gly-Pro-Arg-p-nitroanilide) was from Boehringer  Mannheim. 
Thrombin  Binding  to Heparin-A h'eparin-Sepharose column (1 X 
5 cm) was loaded with  either 20 nM a-thrombin, 20 nM Quick I, 20 
n M  Quick 11, or 20 nM yT-thrombin and eluted with a linear salt 
gradient (10 mM to 1.2 M NaCl) using  a Pharmacia  fast  protein liquid 
chromatography  system.  The  elution profile for all but Quick I1 was 
determined using  a Chromozym-TH hydrolysis  assay. The Quick I1 
elution profile was determined by the  absorbance of each  fraction a t  
280 nm. 
SDS-PAGE of Serpin-Thrombin Complexes-Serpin-thrombin co- 
valent complexes were visualized by SDS-PAGE.  Equal molar (1 p ~ )  
amounts of antithrombin or heparin cofactor I1 were added to a- 
thrombin, Quick I, or Quick I1 and  incubated for 30  min at  37 "C. 
The  resulting SDS-resistant complexes were separated by SDS- 
PAGE using the Laemmli  buffer system  (unreduced)  and 10% poly- 
acrylamide gels stained  with Coomassie Blue (36). 
Thrombin and  Thrombin Quick I Inhibition Assays-Heparin co- 
factor I1 and  antithrombin  inhibition of thrombin  and Quick I in  the 
absence or presence of glycosaminoglycans was performed as de- 
scribed (25,37). Briefly, heparin cofactor I1 (1 or 2 pM) or  antithrom- 
bin (0.5 p ~ )  was  added to  a-thrombin  or Quick I (10 nM) in 20 mM 
Hepes,  pH 7.4, 150 mM NaCI, 0.1% (w/v)  polyethylene glycol, 5 mg/ 
ml bovine serum  albumin, 100  pg/ml Polybrene, a t  25 "C.  At  various 
time  points,  Chromozym-TH was added  (150 nM final  concentration) 
and  the  thrombin hydrolysis of this  substrate was measured at 405 
nm in a VmaX kinetic micro-plate reader (Molecular Devices) and 
compared  to  controls  (thrombin  without  heparin cofactor I1 or  anti- 
thrombin). Glycosaminoglycan template  experiments were performed 
using various concentrations of heparin  or  dermatan  sulfate, 0.5 nM 
a-thrombin or Quick I, and 20 nM heparin cofactor I1 or 5 nM 
antithrombin. Samples were incubated for various intervals before 
addition of substrate with Polybrene. These  experiments were per- 
formed a minimum of three  times  and a representative  experiment  is 
shown. 
Thrombin Quick II  Inhibition Assays-Quick I1 inhibition by hep- 
arin cofactor I1 was performed using a SDS-PAGE  assay. Quick I1 
(1.4 pM) was incubated  with  heparin cofactor I1 (14 p ~ )  in  the absence 
or presence of glycosaminoglycans (5 pg/ml dermatan  sulfate or 10 
pg/ml heparin) for various times a t  room temperature before quencb- 
ing  the  reaction with 2% (w/v) SDS a t  95 "C. The  samples were then 
analyzed by SDS-PAGE. After  Coomassie  Blue staining,  the gels were 
photographed  and  then  scanned  on  an Apple Scanner  using Apple- 
Scan software (Apple Computer).  The  rate of Quick I1 loss (due to 
the formation of the serpin-thrombin complex),  a  kz  value, was 
determined using Scan Analysis (Biosoft Inc., Cambridge, United 
Kingdom). This was repeated a minimum of three times and the 
average kz value is reported. Control experiments with 1.4 p~ a- 
thrombin  and 14 p M  heparin cofactor I1 gave a  calculated k2 value of 
3.8 X 10' M" s-', similar to the 6 x lo2 "' s-l observed using  the 
chromogenic substrate,  Chromozym-TH  (data  not included). 
Molecular Modeling-The three-dimensional  coordinates of D-Phe- 
Pro-Arg chloromethyl ketone-inhibited a-thrombin (FPR-a-throm- 
bin) were a kind gift of Dr. Wolfram  Bode, Max-Planck-Institut  fur 
Biochemie, Martinsried,  Germany (10).  Modeling of Quick I and I1 
was performed using SYBYL (Tripos Associates, St. Louis) and 
AMBER (Version 3.1, U. C. Singh, P. K. Weiner, J. W. Caldwell, 
and P. A. Kollman, Dept. of Pharmaceutical Chemistry,  University 
of California,  San Francisco,  1988). The energy of residues GlyZz6 and 
the  arginyl residue of FPR  (termed Arm41) in  FPR-a-thrombin was 
calculated using the TRIPOS force field in SYBYL. The van der 
Waals energy component of this  calculation  is a measure of the  van 
der  Waals  interaction between the  atoms of 2  residues. For modeling 
of thrombin Quick 11, GlyZz6 of FPR-a-thrombin was changed to Val. 
Next,  the Arg of FPR (Arm41) was changed to a Leu and visually 
fitted  into  the specificity binding  pocket  in  thrombin Quick 11, fitting 
the Leu side chain relative to  the Arg. The energy of ValZz6/Lem41 
(the mutated leucyl residue) in thrombin Quick I1 was calculated. 
The  thrombin Quick I molecule was minimized in a water box using 
AMBER.  First, 1000 cycles of Steepest  Descent minimization were 
performed  and  then  an  additional 2700 cycles of Conjugate Gradient 
minimization. 
RESULTS 
Thrombin Quick Z and ZI Complex  Formation  with  Serpins 
and  Heparin  Binding  Affinity-The serpins  heparin cofactor 
I1 and antithrombin form essentially irreversible covalent 
complexes with the  proteinase  thrombin.  Dysthrombin  char- 
acterization with heparin cofactor I1 and antithrombin re- 
quires defining their  ability  to form bimolecular complexes 
and  to  bind  heparin.  The complexes  formed by incubation of 
thrombin, Quick I or 11, and  heparin cofactor I1 or antithrom- 
bin for 30 min at  37 "C were visualized by SDS-PAGE (Fig. 
1, A and B) .  &-Thrombin (Fig. 1, A and B ,  lane 1; Mr 36,600), 
Quick I (Fig. l A ,  lune 2) ,  and Quick IT (Fig. lB, lane 2 )  formed 
SDS-resistant complexes with  heparin cofactor I1 of M ,  
102,000 (Fig. 1B, lanes 4-6). a-Thrombin-antithrombin  and 
Quick I-antithrombin complexes of M, 93,000 were also  ob- 
served (Fig. 1A, lanes 4 and 5 ) .  Under identical conditions, 
Quick I1 did  not form  a complex with  antithrombin (Fig. lA,  
lane 6 ) .  This suggests that  the G1y226 + Val mutation  prevents 
the normal formation of a bimolecular complex with anti- 
thrombin  but  not with heparin cofactor I1 or, the  antithrom- 
bin does not form  a stable  SDS-resistant complex. 
To confirm that  the  dysthrombin  mutations  do  not  influ- 
ence heparin  binding,  the relative heparin  binding affinity of 
Quick I and Quick 11, compared  to ?,-thrombin and  a-throm- 
bin, was determined.  a-Thrombin, Quick I, Quick 11, and YT- 
thrombin were loaded separately onto a heparin-Sepharose 
affinity column and  eluted with  a linear  salt  gradient (Fig. 2). 
All of the  thrombins  eluted  at a similar salt concentration 
(0.6 M; Fig. 2 ) .  This suggests the  heparin-binding regions  of 
a-thrombin, Quick I, Quick 11, and yT-thrombin are  function- 
ally indistinguishable  under  these  conditions regardless  of the 
protein modifications. 
Antithrombin  and  Heparin Cofactor ZZ Inhibition of Throm- 
bin Quick I-The formation of a SDS-resistant complex in 
Fig. 1 indicates  that Quick I interacts with antithrombin  and 
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TABLE I 
Thrombin Quick I inhibition by heparin cofactor I I  and antithrombin 
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FIG. 1. SDS-resistant complex formation  between  thrombin 
and heparin cofactor I1 or  antithrombin. A, equimolar a-throm- 
bin (a), Quick I ( Q I ) ,  or Quick I1 ( Q I I )  was incubated with antithrom- 
bin ( A T )  for 30 min at  37  "C before boiling in SDS  and separating 
by SDS-PAGE. Lane 1 ,  a-thrombin; 2, Quick I; 3, AT, 4, a-thrombin/ 
AT; 5, Quick I/AT, 6, QuickII/AT. B, equimolar a-thrombin, Quick 
I, or Quick I1 was incubated with heparin cofactor I1 (HC) as described 
above, before boiling in  SDS and separating by SDS-PAGE.  Lane I ,  
a-thrombin; 2, Quick 11; 3, HC; 4, a-thrombin/HC; 5, Quick I/HC; 6, 
Quick II/HC. 
t 
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FIG. 2. Heparin-Sepharose affinity chromatography. a- 
Thrombin (O), yT-thrombin (O), or Quick I (A) were loaded onto a 
heparin-Sepharose fast protein liquid chromatography affinity col- 
umn  and eluted with a linear salt gradient from 10 mM to 1.2 M NaCl. 
Eluted  fractions were assayed for chromogenic activity and  the ab- 
sorbance at  405 nm determined. Quick I1 was loaded onto  the same 
column and  its peak of elution (1) was determined by measuring the 
absorbance at  280 nm. 
heparin cofactor 11, but it is not clear whether the  rate of 
complex formation and  thus, inhibition of thrombin catalytic 
activity, is the same as for a-thrombin. Inhibition rate assays 
showed that in the absence of heparin, antithrombin inhibited 
Quick I at  the same rate  as  a-thrombin  (Table I), as previously 
reported (30). The heparin template curve for antithrombin 
inhibition of Quick I was similar to  a-thrombin, where max- 
imal inhibition occurred a t  a concentration of 1-5 pg/ml 
heparin (Fig. 3). 
The  rate of inhibition of Quick I by heparin cofactor I1  was 
only slightly reduced relative to  a-thrombin in the absence of 
glycosaminoglycans (Table  I).  In  contrast,  in  the presence of 
heparin or dermatan sulfate, heparin cofactor I1 inhibited 
Quick I 220- and 625-fold slower than  a-thrombin, respec- 
tively (Table I). Maximal inhibition of a-thrombin  and Quick 
I occurs at  200 pg/ml for heparin (Fig. 4, top  panel), 1.0 and 
4.0 mg/ml, respectively, for dermatan sulfate (Fig. 4, bottom 
panel). This observation suggests that the Arg residue a t  
Serpin/glycosamino- 
glycan 
Inhibition rate  constant 
(k2 x 10" M-I s - 1 ~  
Human  a-thrombin  Thrombin  Quick I 
AT 0.6  0.6 (l)b 
HC 0.06  0.03 (2) 
AT/heparin' 1900  1200  (1.6) 
HC/heparind 390 1.8 (220) 
HC/dermatan sulfatee 750  1.2 (625) 
a The inhibition rate  constants presented were determined from 
Indicates the -fold difference between the calculated rate for a- 
Heparin  concentrations of 1 and 5 pg/ml, respectively. 
Heparin  concentrations of  500 and 200 pg/ml, respectively. 
the mean of three separate experiments. 
thrombin and Quick I. 
e Dermatan  sulfate  concentrations of 1 and 4 mg/ml, respectively. 
- -  I I 
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FIG. 3. Heparin-dependent  inhibition of thrombin by anti- 
thrombin. Hydrolysis of Chromozym-TH was determined for a- 
thrombin (0) or Quick I (A) in the presence of 10-fold molar excess 
antithrombin and increasing concentrations of heparin. The apparent 
inhibition rate  constant was calculated as M" s" at 25  'C. A repre- 
sentative  experiment is shown. 
position 67 in the /3-loop region of anion  binding exosite-I is 
important  in  the glycosaminoglycan-accelerated inhibition of 
thrombin by heparin cofactor 11. Arg67 is not required for 
heparin-accelerated  inhibition of thrombin by antithrombin. 
Thrombin Quick 11 Complex  Formation  with  Heparin Cofac- 
tor 11-Quick  I1 forms  a SDS-resistant complex with  heparin 
cofactor I1 but  not  antithrombin (Fig. 1, A and B, lune 6) ;  
therefore,  heparin cofactor I1 and  antithrombin  interact with 
this proteinase differently. The  rate of Quick  I1 inhibition by 
heparin cofactor I1 was determined by incubating a molar 
excess of heparin cofactor I1 with Quick I1 for increasing  time 
intervals before analysis by SDS-PAGE. The loss of Quick I1 
was determined by scanning the Coomassie Blue-stained poly- 
acrylamide gel and  an inhibition rate ( kz)  of  2.3 X lo2 "' s-l 
was calculated (Table 11). Formation of the heparin cofactor 
11-Quick  I1 complex was also  accelerated by glycosaminogly- 
cans  (Table 11). Due to  the handling constraints required for 
this method, optimal concentrations for heparin or dermatan 
sulfate acceleration of inhibition were not determined. Thus, 
although Quick I1 has no activity with normal thrombin 
substrates, it does form a complex with the serpin heparin 
cofactor I1 and  its inhibition can be accelerated by glycosa- 
minoglycans. 
It has been suggested that Quick I1 does not react with 
normal a-thrombin arginyl-containing substrates because the 
G1y226 to Val mutation  either blocks access to  the specificity 
binding  pocket or causes other  structural changes within the 
pocket (3,31,38). Our results suggest that Quick I1 does react 
with heparin cofactor 11, a leucyl-containing substrate. To 
investigate this hypothesis further we used computer-assisted 
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FIG. 4. Glycosaminoglycan-dependent inhibition of throm- 
bin by heparin  cofactor 11. Rate of inhibition was determined  for 
tu-thrombin (0) or Quick I (A) in  the  presence of 40-fold molar  excess 
heparin cofactor I1 and increasing concentrations of heparin ( top 
panel)  or  dermatan  sulfate (bottom  panel). The  apparent  inhibition 
rate  constant was calculated as M-' s-l at  25 "C. Note  the differences 
in  scale for the two y axes. Representative  experiments  are shown. 
TABLE I1 
Acceleration of heparin  cofactor 11-Quick II complex  formation  with 
glycosaminoglycans 
Glycosaminoglycan ( k ~  X IO-' M" s-')' 
Rate  constant 
Thrombin Quick I1 Increase 
-fold 
None 2.3 
Heparin (10 pg/ml) 16.7 7.3 
Dermatan  sulfate (5 pg/ml) 6.1  2.6 
"The rate constants for heparin-cofactor I1 complex formation 
with  a-thrombin (3.8 X 10' M" s-') and Quick I1 were determined  as 
described under  "Experimental Procedures." 
three-dimensional molecular modeling. In addition to the 
stereo models, the  interaction between a-thrombin or Quick 
I1 with Arg- or Leu-containing  substrates was further evalu- 
ated by calculating  the  van  der  Waals  interaction  energy  and 
closest distances between these residues. The  van  der  Waals 
energy component of the total energy calculation depends 
only  on  the  interactions between the  atoms of the 2  residues. 
Therefore,  the  interaction e ergies can be used as a qualitative 
measure of the  steric fit of these residues but  not for an  exact 
comparison of the different models. The interaction of a -  
thrombin  with  an  arginyl-containing  substrate,  such  as  anti- 
thrombin, was modeled using the active-site region of FPR- 
a-thrombin.  The  van  der  Waals radii of the G1yZ2'j a-hydro- 
gens  in  a-thrombin do not overlap with  those of the Arg  side 
chain in FPR (Arm41, Fig. 5, top panel). The interaction 
energy of residues G1yZz6 and Arm41 in FPR-a-thrombin  is 
-0.130 kcal/mol with a minimum  inter-atomic  distance of  2.4 
A, indicating a  small stabilization of the complex. 
The  simulation of Quick I1 interacting with heparin cofac- 
tor I1 was performed. We changed G1yZz6 to Val to  represent 
Quick I1 and  the Arg in  FPR  to Leu to give residue  Lem41 in 
FPL.  The van der  Waals radii of the Valzz6  side chain  atoms 
do not overlap with those of the  Lem4l side chain (Fig. 5 ,  
bottom panel). The van der Waals interaction energies for 
Lem41 (Leu substituted for Arg) with Valzz6 of Quick I1 is 
slightly  destabilizing at  6.0 kcal/mol and  the closest distance 
between  Lem41/ValZz6 is 3.0 A. The molecular modeling sug- 
gests  that  the  reactive-site Leu of heparin cofactor I1 would 
not extend far enough into  the specifity binding pocket to 
collide with Valzz6 of Quick 11. Therefore,  heparin cofactor I1 
forms complexes with the mutant thrombin. In contrast, 
antithrombin  (and  other  substrates)  with a  much  longer re- 
active-site Arg side chain shows no reactivity  with Quick I1 
and would not  enter  the  substrate  binding pocket  (modeling 
not  shown).  The  results  obtained by molecular modeling of 
the GlyZz6 * Val mutation  in  a-thrombin  are  consistent with 
our  inhibition assays  using heparin cofactor I1 and  antithrom- 
bin. 
DISCUSSION 
This  study was undertaken in order  to  better  understand 
how thrombin interacts with heparin cofactor I1 and anti- 
thrombin.  Our  results focus on two dysfunctional thrombins, 
Quick I and Quick 11, and how the specific regions of the 
mutant  proteins  are involved in  the physiological regulation 
of thrombin by heparin cofactor I1 and  antithrombin.  The 
serpin  heparin  cofactor I1 specifically inhibits  thrombin,  and 
inhibition  is accelerated by the glycosaminoglycans heparin 
and  dermatan  sulfate.  The  mechanism of heparin cofactor 11/ 
glycosaminoglycan inhibition of thrombin differs from that 
described for the major blood plasma thrombin inhibitor, 
antithrombin (25-28). Heparin cofactor I1 contains  an acidic 
amino-terminal domain that is not found in other serpin 
family  members. This region of the  protein is necessary  for 
optimal glycosaminoglycan-mediated  acceleration of throm- 
bin  inhibition. Mutagenesis studies of heparin cofactor I1 by 
both van  Deerlin and Tollefsen (26)  and Ragg et al. (27, 28) 
suggest that  changing residues in  this acidic amino  terminus 
to basic residues decreases the acceleration of inhibition in 
the presence of glycosaminoglycans. The acidic amino  termi- 
nus of heparin cofactor I1 is proposed to  interact with anion 
binding exosite-I in a-thrombin. This hypothesis is further 
supported by the work of Rogers et al. (25), where inhibition 
of thrombin by heparin cofactor I1 in  the presence of glyco- 
saminoglycans is reduced with yT-thrombin, a proteolyzed 
thrombin molecule missing most of anion  binding  exosite-I, 
specifically, the @loop region. The  current model of heparin 
cofactor I1 interaction with thrombin suggests that  the gly- 
cosaminoglycan bridges the glycosaminoglycan-binding re- 
gions of heparin cofactor I1 and  thrombin,  the acidic amino 
terminus of heparin cofactor I1 is displaced and is then able 
to  interact  with  anion  binding exosite-I of thrombin (25-28). 
Thus, collective stabilization ("double bridging") of the  inter- 
action between heparin cofactor I1 and thrombin by the 
glycosaminoglycan and  the  amino  terminus of heparin cofac- 
tor I1 results  in  the  dramatic acceleration of inhibition. 
Thrombin Quick I  possesses  a  single amino acid substitu- 
tion (Arg'j7 + Cys) in the @-loop region of anion binding 
exosite-I (15). It  reacts normally  with antithrombin  and  hep- 
arin cofactor I1 and  binds  heparin with the  same  affinity  as 
a-thrombin.  Heparin cofactor I1 inhibition of Quick I  relative 
to  a-thrombin  is  essentially  normal  in  the absence  of glyco- 
saminoglycans. In  the presence of heparin or dermatan sul- 
fate, however, the  rate  enhancement for Quick I inhibition  is 
reduced  relative to  that for a-thrombin.  This is in  contrast  to 
antithrombin where the  rate of inhibition of a-thrombin  and 
Quick I is the  same  in  the presence or absence of heparin. 
Therefore, a different mechanism must be involved in the 





FPL-Thrombin Quick II 
FIG. 5. Molecular modeling of a-thrombin and Quick I1 with a P1 Leu substrate. Computer-assisted three-dimensional molecular 
modeling (stereo views) of the substrate binding pocket of a-thrombin with FPR (top  panel) and Quick I1 with FPL (bottom panel). CY- 
Thrombin  and Quick I1 residues are labeled on the right with the substrate P1 Arg residue (Arm41) and Leu (Lem41) labels on the left. 
glycosaminoglycan-accelerated inhibition of thrombin by hep- 
arin cofactor I1 compared to antithrombin. Our results are 
consistent with the p-loop region of Quick I participating  in 
heparin cofactor I1 inhibition of thrombin  in  the  presence of 
glycosaminoglycans. 
The Arg'j7 to Cys substitution  in Quick I must  result  in a 
structural  change  in  the p-loop region of the  thrombin mole- 
cule. Normally, Arg67 and Glue' form a salt bridge, which 
presumably stabilizes this region of the molecule (10). The 
Cys at  residue 67 in the  variant  thrombin  cannot  form  this 
interaction. The resulting structure of this domain can be 
predicted by computer-assisted molecular  modeling  where the 
thrombin molecule was minimized upon  substituting Cys for 
Arg67 (Fig. 6).  The top  panel is a stereo view of the  &-thrombin 
@-loop region and  the bottom panel is the  same region of Quick 
I. The Cys permits more  flexibility to  the region and probably 
alters  the p-loop conformation such that efficient interaction 
with heparin cofactor I1 in the presence of glycosaminoglycan 
does not occur. 
The  results  presented  here also demonstrate  heparin cofac- 
tor 11's ability  to  interact  with Quick 11 where other "classic" 
thrombin  substrates fail. Quick I1 has  dramatically impaired 
catalytic  activity  toward  normal  thrombin  substrates (30,31). 
It has 103-fold lower affinity for hirudin, although it binds 
hirudin lacking the  amino-terminal residues  only  16-fold  less 
than a-thrombin (38). Quick I1 also binds platelets with 
reduced affinity (39). Henriksen and Mann (31) previously 
demonstrated  that Quick I1 was able to inefficiently hydrolyze 
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the elastase substrate succinyl-Ala-Ala-Pro-Leu-p-nitroani- 
lide. Our  results  demonstrate  that Quick I1 appears  to  bind 
heparin normally, but  it does not  interact  with  the  thrombin 
chromogenic substrate  or form a complex with antithrombin. 
We observe that heparin cofactor 11-Quick I1 complex for- 
mation  can be accelerated by glycosaminoglycans. The  obser- 
vation  that  heparin cofactor I1 forms a complex with Quick 
I1 which is stable in SDS can be better  understood by molec- 
ular modeling which suggests that  the  reactive-site P1 Leu 
(Leu-Ser) of heparin cofactor I1 would not  extend as far  into 
the primary  substrate  binding  pocket as a normal  thrombin 
substrate possessing an Arg in  the P1 position  (Arg-Ser). The 
Val substitution in Quick I1 is postulated to disturb the 
conformation of the specificity  pocket in  part by disrupting 
Asp"' (3, 38). The Asp'*' carboxylate group would normally 
interact ionically with the P1 Arg guanidinium group to 
contribute  to  the specificity of the Arg-Ser substrate.  It  has 
also been concluded that the Quick I1 mutation disrupts 
surface residues resulting  in  its reduced affinity  for  platelets 
and  hirudin (38, 39). 
In conclusion, heparin cofactor I1 clearly  differs  from anti- 
thrombin during thrombin regulation and inhibition, espe- 
cially in  the  presence of glycosaminoglycans. The  mechanism 
of glycosaminoglycan acceleration for thrombin  inhibition by 
heparin cofactor I1 is consistent with ternary complex for- 
mation which then  makes available the  unique acidic domain 
in  heparin cofactor I1 for interaction  with  the @-loop region 
of thrombin.  Furthermore,  subtle  distinctions  must  be  present 
in  the  heparin cofactor I1 reactive-site  domain  compared to 
that  in  antithrombin for thrombin active-site  recognition.  A 
question  that  remains  is how these  thrombin exosites partic- 
ipate in uiuo during  inhibition.  It  is likely that cellular and 
extracellular  matrix  thrombin  interactions involved in local- 
ization of the  proteinase  are  important for directing physio- 
logical inhibition of thrombin by heparin cofactor I1 and 
antithrombin  and  the acceleration of inhibition by glycosa- 
minoglycans. 
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